ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

REPL Replimune Group Inc

6.95
0.39 (5.95%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Replimune Group Inc REPL NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.39 5.95% 6.95 09:00:00
始値 安値 高値 終値 前日終値
6.80 6.605 7.08 6.95 6.56
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/0806:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
2024/4/0421:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
2024/3/2620:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
2024/3/0622:00GLOBEReplimune to Present at the American Association for Cancer..
2024/3/0522:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
2024/2/1421:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/0822:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/2/0822:05EDGAR2Form 8-K - Current report
2024/2/0822:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
2024/1/1618:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
2024/1/1617:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
2024/1/0822:00EDGAR2Form 8-K - Current report
2023/12/2822:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
2023/12/2707:15EDGAR2Form 8-K - Current report
2023/12/0521:19EDGAR2Form 8-K - Current report
2023/12/0521:00GLOBEReplimune Shares Initial Primary Analysis Results from..
2023/11/1810:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1810:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0823:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
2023/11/0807:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0722:15EDGAR2Form 8-K - Current report
2023/11/0722:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
2023/11/0408:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
2023/9/2109:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/2109:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/9/2005:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
2023/9/1921:15EDGAR2Form 8-K - Current report
2023/9/1921:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
2023/9/1410:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/0722:17EDGAR2Form 8-K - Current report
2023/8/2509:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/1609:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/8/0322:04EDGAR2Form 8-K - Current report
2023/8/0321:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
2023/8/0321:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0321:09EDGAR2Form 8-K - Current report
2023/8/0321:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
2023/8/0121:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
2023/8/0105:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
2023/7/2709:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
2023/7/2706:08EDGAR2Form ARS - Annual Report to Security Holders
2023/7/2706:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/7/2706:02EDGAR2Form DEF 14A - Other definitive proxy statements
2023/7/2021:56EDGAR2Form 8-K - Current report
2023/7/2021:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
2023/7/1210:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/7/1105:27EDGAR2Form 144 - Report of proposed sale of securities
2023/6/0623:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
2023/6/0521:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
2023/6/0403:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..

最近閲覧した銘柄

Delayed Upgrade Clock